Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Aspirin and Clopidogrel for Patients with Atrial Fibrillation After Left Atrial Appendage Closure

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two different treatments for patients with Atrial Fibrillation, a condition where the heart beats irregularly. The study involves patients who have undergone a procedure called left atrial appendage closure (LAAC), which is used to prevent strokes in people who cannot take blood thinners. The trial will compare the effectiveness of two antithrombotic strategies: one group will receive aspirin alone, while the other group will receive a combination of aspirin and clopidogrel, a medication that helps prevent blood clots.

The purpose of the study is to evaluate how well these treatments work in preventing new ischemic lesions in the brain, which are areas of tissue damage caused by a lack of blood flow. These lesions will be monitored using MRI scans of the brain, taken within 24 hours after the procedure and again after three months. The study will also look at other outcomes, such as any new symptoms of stroke or bleeding events, and assess the overall health and cognitive function of the participants over the three-month period.

Participants in the study will be monitored closely, with regular check-ups and assessments to ensure their safety and to gather data on the effectiveness of the treatments. The trial aims to provide valuable information on the best strategy for preventing complications in patients with atrial fibrillation who have undergone LAAC, ultimately helping to improve patient care and outcomes.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, medical condition, and consent.

    The study focuses on patients with a condition called atrial fibrillation who have undergone a procedure known as left atrial appendage closure.

  2. Step 2

    Initial assessment

    An initial brain MRI scan is performed within 24 hours after the procedure to check for any ischemic lesions, which are areas of restricted blood flow in the brain.

  3. Step 3

    Medication administration

    Two different medication strategies are evaluated: one group receives aspirin alone, and the other group receives a combination of aspirin and clopidogrel.

    Aspirin is administered as KARDEGIC 160 mg oral solution, and clopidogrel is administered as Plavix 75 mg film-coated tablets.

    These medications are taken orally as prescribed by the study protocol.

  4. Step 4

    Follow-up assessments

    A follow-up brain MRI scan is conducted after 3 months to compare with the initial scan and assess any new ischemic lesions.

    Neurological examinations are performed at day 1 and month 3 to check for any symptoms of cerebral events such as strokes or transient ischemic attacks.

  5. Step 5

    Additional evaluations

    Cognitive assessments are conducted using the Montreal Cognitive Assessment (MoCA) scale at day 1 and month 3.

    The presence of any thrombus on the prosthesis and other related evaluations are performed using a cardiac CT scan at 3 months.

  6. Step 6

    Treatment compliance

    Compliance with the medication regimen is assessed at month 3 by comparing the medications taken with those prescribed.

    This compliance is analyzed in relation to any thromboembolic or hemorrhagic events that may occur.

Who can join the trial?

5 criteria

  • Male or female patients who need a procedure called **LAAC**. This is a treatment for a heart condition where a small part of the heart is closed off to prevent blood clots.
  • Must be **18 years or older**.
  • Must provide **written informed consent**, which means you agree to participate after being fully informed about the study.
  • Approval from a **heart team**, which is a group of doctors including heart specialists and brain specialists, who agree that you should not take blood-thinning medications.
  • Must be registered under the **social security system**, which means you have access to healthcare services.

Who cannot join the trial?

8 criteria

  • Patients with a history of **bleeding disorders**. This means any condition that makes it hard for the blood to clot properly.
  • Patients who have had a **stroke** in the last 6 months. A stroke is when blood flow to a part of the brain is stopped, causing brain cells to die.
  • Patients with severe **kidney disease**. This is when the kidneys are not working well enough to clean the blood properly.
  • Patients with severe **liver disease**. This is when the liver is not working well enough to perform its normal functions.
  • Patients who are allergic to **aspirin** or **clopidogrel**. These are medications used to prevent blood clots.
  • Patients who are pregnant or breastfeeding. This means women who are expecting a baby or are nursing a baby.
  • Patients who are participating in another clinical trial. This means being involved in another study at the same time.
  • Patients with any other condition that the study doctors think would make it unsafe to participate. This means any health issue that could cause problems if the patient joins the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Aspirin

    is a medication used to reduce pain, fever, or inflammation. In this trial, it is being used as an antithrombotic strategy to prevent blood clots following a procedure called left atrial appendage closure (LAAC). The study aims to see how effective aspirin is in preventing ischemic lesions in the brain after the procedure.

  • Clopidogrel

    is another medication that helps prevent blood clots. It is often used in combination with aspirin to enhance the antithrombotic effect. In this trial, clopidogrel is being used alongside aspirin to evaluate if the combination is more effective than aspirin alone in preventing ischemic lesions in the brain after the LAAC procedure.

What is already known about the treatment

  • Aspirin

    Aspirin is typically administered orally in tablet form. It is widely used in medicine as an antiplatelet agent to prevent blood clots. The main therapeutic indication for aspirin in this context is to reduce the risk of stroke in patients with atrial fibrillation following left atrial appendage closure. At the molecular level, aspirin works by inhibiting the enzyme cyclooxygenase, which in turn reduces the formation of thromboxane, a molecule that promotes platelet aggregation. It is classified as a non-steroidal anti-inflammatory drug (NSAID) with antiplatelet properties.

  • Clopidogrel

    Clopidogrel is administered orally, usually in tablet form. It is a well-established medication in the medical field, primarily used as an antiplatelet agent. The main therapeutic indication for clopidogrel in this trial is to prevent ischemic events in patients with atrial fibrillation after left atrial appendage closure, when used in combination with aspirin. Clopidogrel works by inhibiting the P2Y12 receptor on platelets, which prevents platelet aggregation and reduces the risk of clot formation. It is classified as a thienopyridine antiplatelet drug.

Investigated diseases

Atrial Fibrillation – Atrial fibrillation is a common heart rhythm disorder where the heart's upper chambers (atria) beat irregularly and often rapidly. This irregular rhythm can lead to poor blood flow and may cause blood clots to form in the heart. These clots can travel to other parts of the body, potentially causing strokes or other complications. The condition can be persistent or occur in episodes, and it may be associated with symptoms like palpitations, fatigue, or shortness of breath. Over time, atrial fibrillation can weaken the heart and lead to heart failure if not managed properly. It is often related to other heart conditions, high blood pressure, or age-related changes in the heart.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515774-27-00Protocol codeCHUBX2017/29Estimated enrolment60 patientsSponsorCentre Hospitalier Universitaire De Bordeaux

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).